XThis page contains elements that are not optimised for mobile viewing. Click the link below to view the page in desktop mode.
Desktop mode

This page is not available in English


Click here to see the Danish page '▼Xeljanz® (tofacitinib): Øget risiko for alvorlige kardiovaskulære hændelser og maligniteter ved brug af tofacitinib sammenlignet med TNF-alfa-hæmmere' Go to English frontpage